StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note released on Friday morning. The firm issued a buy rating on the stock.

Trinity Biotech Stock Performance

Trinity Biotech stock opened at $1.99 on Friday. The business’s 50-day simple moving average is $2.54 and its 200-day simple moving average is $2.22. Trinity Biotech has a 52 week low of $1.49 and a 52 week high of $4.59.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.10. The business had revenue of $15.84 million for the quarter, compared to analyst estimates of $15.75 million. As a group, research analysts predict that Trinity Biotech will post -1.91 earnings per share for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.